Psyched: Groundbreaking Phase 3 Results On MDMA, Small Pharma, Wesana Go Public, Gilgamesh Raises $27M
Last week, the psychedelics space was moved by results from the world’s first Phase 3 clinical study of a scheduled psychedelic compound.
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
All news is property of their respective owners.
